Aurobindo Pharma · NSE: AUROPHARMA · BSE: 524804

Q2 FY23 results · Jul–Sep 2022

Aurobindo Pharma reported revenue from operations of ₹5,739.37 crore (down 3.4% from Q2 FY22) and net profit of ₹410.37 crore (down 41.1% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY23	Q2 FY22	YoY	Q1 FY23	QoQ
Revenue from operations	5,739.37	5,941.92	−3.4%	6,235.92	−8.0%
Other income	57.19	96.58	−40.8%	40.62	+40.8%
Total income	5,796.56	6,038.50	−4.0%	6,276.54	−7.6%
Profit before share of associates & JVs and tax	524.59	978.67	−46.4%	682.96	−23.2%
Share of profit/(loss) of associates & JVs	(1.23)	(11.05)		(3.97)
Net profit for the period	410.37	696.71	−41.1%	520.38	−21.1%
Attributable to shareholders of the company	409.45	696.99	−41.3%	520.54	−21.3%
EPS, basic (₹)	6.99	11.89	−41.2%	8.88	−21.3%
Net margin (%)	7.2	11.7		8.3

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY23	Q2 FY22	YoY	Q1 FY23	QoQ
Revenue from operations	3,025.66	2,883.18	+4.9%	2,786.92	+8.6%
Other income	55.86	82.37	−32.2%	38.71	+44.3%
Total income	3,081.52	2,965.55	+3.9%	2,825.63	+9.1%
Profit before tax	223.76	320.48	−30.2%	170.07	+31.6%
Net profit for the period	164.63	197.68	−16.7%	122.16	+34.8%
EPS, basic (₹)	2.81	3.37	−16.6%	2.08	+35.1%
Net margin (%)	5.4	6.9		4.4

Consolidated

Filed with BSE: 13 Nov 2022, 13:36 IST
Board meeting: 12 Nov 2022
Period: 01 Jul 2022 to 30 Sep 2022
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 13 Nov 2022, 13:36 IST
Board meeting: 12 Nov 2022
Period: 01 Jul 2022 to 30 Sep 2022
Review status: Unaudited
Source: XBRL filing on BSE